Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: Results of the French Robotic Surgery Group of GETTEC.
Transoral robotic surgery (TORS) is an option to treat supraglottic squamous cell carcinomas (SCCs). We studied the oncologic outcomes after TORS for supraglottic laryngectomy (SGL). We conducted a multicenter observational study of SGL using TORS for patients with supraglottic SCC with at least 2 years of follow-up. One hundred twenty-two patients were included in our study. Mean follow-up was 42.8 months. Local control was 94.3% at 2 years and 90.2% at 5 years. Overall survival and disease-free survival were 86.9% and 95.1% at 2 years, and 78.7% and 94.3% at 5 years, respectively. Sixty-three patients (51.6%) received adjuvant radiotherapy. For 16 of them, this was due to close or positive margins. Local control rate after TORS SGL was at least equivalent to what has been described in the literature for open or transoral laser surgery, or with radiotherapy. Using TORS seems to be an effective therapeutic treatment of early-stage and intermediate-stage supraglottic SCCs.